Ocular Therapeutix (OCUL) Misses Q2 EPS by 4c

Ocular Therapeutix (NASDAQ: OCUL) reported Q2 EPS of ($0.25), $0.04 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $11.7 million versus the consensus estimate of $11.6 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• Greenbrier Cos. (GBX) Reports In-Line Q3 EPS
• Biogen expects $164M R&D charge to hit Q2 2026 earnings
• Lindsay, Palantir rise premarket; Ouster, Bending Spoons fall